HW

Hao-Tien Wang, PhD

Director, Intellectual Property and Legal Affairs

GenomeFrontier Therapeutics

Therapeutic Areas

GenomeFrontier Therapeutics Pipeline

DrugIndicationPhase
GF-CART01B cell malignanciesPreclinical
GF-CART02Multiple myelomaPreclinical
GF-CART03Solid tumorsPreclinical